Characteristics associated with AKI in hospitalized patients with SCA
| Variables . | N . | No AKI . | N . | AKI . | P . |
|---|---|---|---|---|---|
| At the time of hospitalization . | |||||
| Age, median (IQR), y | 74 | 30 (24-37) | 63 | 38 (28-48) | <.0001 |
| Total number of hospitalizations, median (IQR) | 74 | 9 (3-25) | 63 | 17 (6-29) | .08 |
| Diabetes mellitus history, n (%) | 74 | 2 (3) | 63 | 2 (3) | .9 |
| Hypertension history, n (%) | 74 | 8 (11) | 63 | 10 (16) | .4 |
| Hydroxyurea use, n (%) | 74 | 34 (46) | 63 | 34 (54) | .5 |
| ACE inhibitor or ARB therapy, n (%) | 74 | 12 (16) | 63 | 12 (19) | .7 |
| Outpatient NSAID use, n (%) | 74 | 23 (31) | 63 | 17 (27) | .6 |
| Chronic transfusion therapy, n (%) | 74 | 9 (12) | 63 | 12 (19) | .3 |
| Systolic blood pressure, median (IQR), mm Hg | 74 | 122 (113-140) | 63 | 116 (106-127) | .008 |
| WBC count, median (IQR), ×103/µL | 74 | 11.1 (9.0-14.6) | 63 | 13.7 (11.0-17.2) | .001 |
| Hemoglobin, median (IQR), g/dL | 74 | 8.5 (7.3-9.6) | 63 | 7.9 (7.1-8.6) | .02 |
| Indirect bilirubin, median (IQR), mg/dL | 55 | 1.9 (1.3-4.0) | 53 | 2.5 (1.5-4.0) | .4 |
| Hemoglobinuria, n (%) | 44 | 9 (20) | 40 | 23 (58) | .0005 |
| Serum creatinine, median (IQR), mg/dL | 74 | 0.7 (0.5-0.8) | 63 | 1.2 (0.8-1.4) | <.0001 |
| Urine albumin, median (IQR), mg/g creatinine | 69 | 38 (12-159) | 58 | 91 (23-317) | .05 |
| Variables . | N . | No AKI . | N . | AKI . | P . |
|---|---|---|---|---|---|
| At the time of hospitalization . | |||||
| Age, median (IQR), y | 74 | 30 (24-37) | 63 | 38 (28-48) | <.0001 |
| Total number of hospitalizations, median (IQR) | 74 | 9 (3-25) | 63 | 17 (6-29) | .08 |
| Diabetes mellitus history, n (%) | 74 | 2 (3) | 63 | 2 (3) | .9 |
| Hypertension history, n (%) | 74 | 8 (11) | 63 | 10 (16) | .4 |
| Hydroxyurea use, n (%) | 74 | 34 (46) | 63 | 34 (54) | .5 |
| ACE inhibitor or ARB therapy, n (%) | 74 | 12 (16) | 63 | 12 (19) | .7 |
| Outpatient NSAID use, n (%) | 74 | 23 (31) | 63 | 17 (27) | .6 |
| Chronic transfusion therapy, n (%) | 74 | 9 (12) | 63 | 12 (19) | .3 |
| Systolic blood pressure, median (IQR), mm Hg | 74 | 122 (113-140) | 63 | 116 (106-127) | .008 |
| WBC count, median (IQR), ×103/µL | 74 | 11.1 (9.0-14.6) | 63 | 13.7 (11.0-17.2) | .001 |
| Hemoglobin, median (IQR), g/dL | 74 | 8.5 (7.3-9.6) | 63 | 7.9 (7.1-8.6) | .02 |
| Indirect bilirubin, median (IQR), mg/dL | 55 | 1.9 (1.3-4.0) | 53 | 2.5 (1.5-4.0) | .4 |
| Hemoglobinuria, n (%) | 44 | 9 (20) | 40 | 23 (58) | .0005 |
| Serum creatinine, median (IQR), mg/dL | 74 | 0.7 (0.5-0.8) | 63 | 1.2 (0.8-1.4) | <.0001 |
| Urine albumin, median (IQR), mg/g creatinine | 69 | 38 (12-159) | 58 | 91 (23-317) | .05 |
| During hospitalization . | |||||
|---|---|---|---|---|---|
| NSAID use, n (%) | 74 | 27 (36) | 63 | 13 (21) | .04 |
| Intravenous contrast use, n (%) | 74 | 9 (12) | 63 | 6 (10) | .6 |
| Vancomycin use, n (%) | 74 | 5 (7) | 63 | 17 (27) | .001 |
| β-Lactam antibiotic use, n (%) | 74 | 28 (38) | 63 | 24 (38) | .9 |
| Sepsis, n (%) | 74 | 1 (1) | 63 | 2 (3) | .5 |
| During hospitalization . | |||||
|---|---|---|---|---|---|
| NSAID use, n (%) | 74 | 27 (36) | 63 | 13 (21) | .04 |
| Intravenous contrast use, n (%) | 74 | 9 (12) | 63 | 6 (10) | .6 |
| Vancomycin use, n (%) | 74 | 5 (7) | 63 | 17 (27) | .001 |
| β-Lactam antibiotic use, n (%) | 74 | 28 (38) | 63 | 24 (38) | .9 |
| Sepsis, n (%) | 74 | 1 (1) | 63 | 2 (3) | .5 |
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NSAID, nonsteroidal anti-inflammatory drug.